Evidence map›Paper›PMID 27559271›Full record

ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2014

Novel non-cyclooxygenase inhibitory derivatives of naproxen for colorectal cancer chemoprevention.

Tarek Aboul-Fadl, Suliman S Al-Hamad, Kevin Lee, Nan Li, Bernard D Gary, Adam B Keeton, Gary A Piazza, Mohammed K Abdel-Hamid

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Tarek Aboul-FadlDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Suliman S Al-HamadDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Kevin LeeDrug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Nan LiDepartment of Biochemistry, The University of Alabama at Birmingham, Birmingham, AL 35205, USA.
Bernard D GaryDrug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Adam B KeetonDrug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Gary A PiazzaDrug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Mohammed K Abdel-HamidDepartment of Medicinal Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
University of South Alabama · USKing Saud University · SAUniversity of Alabama at Birmingham · USUniversity of Newcastle Australia · AU

Funding

Selective anti-cancer activity of sulindac derivatives on KRAS mutant colon tumor cells by inducing ROSR01CA131378 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2008 to 2019
$5.2M
Development of a novel sulindac amide for colorectal cancer chemopreventionR01CA148817 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2010 to 2015
$2.4M
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer ChemopreventionR01CA155638 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2012 to 2017
$2.3M
NCI NIH HHS R01 CA131378NCI NIH HHS R01 CA148817NCI NIH HHS R01 CA155638
6 · The paper itself

Abstract

A structure-based medicinal chemistry strategy was applied to design new naproxen derivatives that show growth inhibitory activity against human colon tumor cells through a cyclooxygenase (COX)-independent mechanism. In vitro testing of the synthesized compounds against the human HT-29 colon tumor cell line revealed enhanced growth inhibitory activity compared to the parent naproxen with

Indexed as

ApoptosisChemopreventionColorectal cancerCyclooxygenaseNaproxenNSAIDsPharmcophoreUlcerogenicity

Identifiers

PMID27559271
PMCPMC4993210
OpenAlexW1981101828

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.